Alemtuzumab vs ATG for T-Cell Depletion in Sibling Donor Reduced Intensity Haematopoietic Stem Cell Transplantation (RIC HSCT) for the Treatment of Acute Myeloid Leukaemia and Myelodysplastic Syndrome

Abstract

We report the results of a retrospective analysis on 83 patients who underwent HLA-matched sibling donor RIC HSCT receiving either ATG or alemtuzumab. All patients received a uniform protocol of fludarabine and busulfan. For T-cell depletion/GVHD prophylaxis 48 patients received alemtuzumab(20mg x 5 days IV) followed by cyclosporin A post-transplant. 35 patients received ATG(Thymoglobulin, Genzyme)(total 6mg/kg over 3 days IV) followed by methotrexate/cyclosporine A post-transplant.